IL17A and psoriasis vulgaris: Investigated TNF inhibitors (adalimumab and etanercept) and IL-17 and IL-12/23 inhibitors (ixekizumab, secukinumab, and ustekinumab) evaluated in pediatric plaque psoriasis achieve superior efficacy over control arms, measured by PASI75 and PASI90 after 3 months of treatment.